Effectiveness of quantitative MAA SPECT/CT for the definition of vascularized hepatic volume and dosimetric approach: Phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres

Nuclear Medicine Communications

Volumn 32, Issue 12, 2011, Pages 1245-1255

  Garin, Etienne ^a,b,c   Lenoir, Laurence ^a   Rolland, Yan ^a   Laffont, Sophie ^a,c   Pracht, Marc ^a   Mesbah, Habiba ^a   Porée, Philippe ^a   Ardisson, Valérie ^a,c   Bourguet, Patrick ^a,b   Clement, Bruno ^c   Boucher, Eveline ^a,c  

^a Department of Medical Informatics   (France)

^b UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^c Univ Rennes   (France)

Author keywords

dosimetry; hepatocellular carcinoma; radioembolization; single photon emission computed tomography computed tomography; yttrium 90

Indexed keywords

MACROSALB TC 99M; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; THERASPHERE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG UPTAKE; FEMALE; HEPATIC ARTERY; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; LIVER ANGIOGRAPHY; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER WEIGHT; MALE; MEASUREMENT ERROR; QUANTITATIVE ANALYSIS; RADIATION ABSORPTION; RADIATION DOSE; RADIATION MEASUREMENT; RADIOACTIVITY; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULARIZATION;

AGED; ALBUMINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; ORGAN SIZE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 80455174658     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834a716b     Document Type: Article

References (21)

1. Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nature Review 2010; 7:41-49.
2. Raoul JL, Guyader D, Bretagne JF, Duvauferrier R, Bourguet P, Bekhechi D, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994; 35:1782-1787.
3. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26:1156-1161.
4. Houle S, Yip TCK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, et al. Hepatocellular carcinoma: a pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172:857-860.
5. Shepherd FA, Rotstein LE, Houle S, Yip TC, Sniderman KW, Paul K. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70:2250-2254.
6. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002; 13 (9 Pt 2):S223-S229.
7. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006; 17:1251-1278.
8. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, et al. Angiographic considerations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 2005; 16:911-935.
9. Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P, Antoch G. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 2009; 50:688-692.
10. Garin E, Rolland Y, Boucher E, Ardisson V, Laffont S, Boudjema K, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging 2010; 37:453-461.
11. Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med 2010; 51:1206-1212 [Epub 21 July 2010].
12. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52-64.
13. Gré goire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: a new standard? J Nucl Med 2007; 48 (Suppl 1):68S-77S.
14. Erdi YE, Wessels BW, Loew MH, Erdi AK. Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Cancer Res 1995; 55 (23 Suppl):5823s-5826s.
15. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005; 46:1342-1348.
16. Pé rez-López B, Vega-González IF, Estrada-Lobato E, Pé rez-Molina JJ, Torres- Mendoza BM, Medina LA. Volume-of-interest assessment of oncologic response using 18F-FDG PET/CT: a phantom study. J Nucl Med Technol 2011; 39:14-18 [Epub 14 February 2011].
17. Sato KT, Omary RA, Takehana C, Ibrahim S, Lewandowski RJ, Ryu RK, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol 2009; 20:1564-1569.
18. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49:1185-1193.
19. Becker S, Laffont S, Rolland Y, Vitry F, Lecloirec J, Boucher E, et al. Dosimetric evaluation and therapeutic response to vectorized internal radiation therapy of hepatocarcinomas using iodine-131 labelled lipiodol. Nucl Med Comm 2008; 29:815-825.
20. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
21. Gray BN, Burton MA, Kelleher D, Klemp P, Matz M. Tolerance of the liver to the effects of yttrium-90 radiation. Int J Radiat Oncol Biol Phys 1990; 18:619-623.